Navigation Links
Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
Date:11/9/2013

ATLANTA, GA Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. This data will be presented at the American Society of Nephrology's Kidney Week 2013 in Atlanta, GA.

Chronic kidney disease (CKD) is the slow loss of kidney function over time. The main function of the kidneys is to remove wastes and excess water from the body. When chronic kidney failure reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can accumulate in the body, and a patient will need to undergo hemodialysis (dialysis) a machine that filters wastes, salts and fluid from the blood. A common problem for patients on dialysis is iron deficiency. The body needs a certain amount of iron for overall good health and healthy blood cells, but excess iron gradually builds up in tissues and organs, eventually damaging them. Standard, current care for dialysis patients with iron deficiency is to intravenously inject 100 mg of iron into the bloodstream. But this method can result in oxidative stress and harm to people on dialysis.

Steven Fishbane, MD, and Azzour Hazzan, MD from the North Shore-LIJ Health System's Division of Nephrology in New York, in collaboration with Ajay Singh, MD, associate professor at Harvard Medical School, conducted two Phase 3 trials, CRUISE-1 and CRUISE-2, which demonstrated, in 300 patients in each trial, that Triferic administered at each dialysis treatment for up to 48 weeks effectively delivers iron and maintains the body's hemoglobin concentration constant. Triferic is a novel iron compound that has a unique mode of action in that it is delivered to the patient via their dialysis treatment as opposed to intravenous delivery. Triferic gradually delivers iron to the bone marrow and maintains hemoglobin without the rapid flux of i
'/>"/>

Contact: Emily Eng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Investigational agent targets gene signaling pathways to improve response for patients with CLL
2. Method patent issued for investigational new class of pain medication
3. Investigational malaria vaccine found safe and protective
4. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
5. Investigational PARP inhibitor promising in BRCA-related cancers
6. NIH launches trial of investigational genital herpes vaccine
7. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
8. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Lower-Dose Radioiodine Effective Against Thyroid Cancer
11. Aspirin as Effective as Warfarin for Heart Failure: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... emissions will reduce other harmful air pollution and ... new study released today. The research shows that, ... final Clean Power Plan, the power plant standards ... and hundreds of heart attacks in the United ... Co-benefits of Carbon Standards for Existing Power Plants, ...
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 VisitandCare.com ... in Turkey has gone up more than 79 percent ... medical tourism company also reported total revenue tripled for ... , The company’s professional strategy has allowed them to ... ultimately designed for patient comfort and privacy — with ...
Breaking Medicine News(10 mins):Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... available through Lifeboat,s reseller network; Services seen as complement to ... ... Northglenn, CO (PRWEB) March 5, 2009 -- ImageDoc USA, ... a distribution agreement with Lifeboat Distribution, an international specialty software ...
... patients with better results, lower cost, less discomfort, faster recovery ... ... Boca Raton, FL (PRWEB) March 5, 2009 -- A new ... improve hair transplant surgery for male and female patients., , ...
... and resources for patients and their families , ... ... brain injuries each year through falls, traffic accidents, sports and other ... (BIAA), which is observing National Brain Injury Awareness Month in March ...
... evaluate the effectiveness of current continuing medical education ... recommendations on how those practices need to change ... of CHEST , the peer-reviewed journal of ... of Continuing Medical Education: American College of Chest ...
... also been accepted for publication as an original article ... 4 NewCardio, Inc. (OTC Bulletin Board: NWCI) a ... Ihor Gussak, NewCardio,s Vice President and Chief Medical Officer, ... 58th Annual Scientific Session in Orlando on March 29, ...
... The following is a statement by Matthew ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The House Energy and Commerce Committee today ... historic action to reduce tobacco use by approving ... authority over tobacco products. Today,s 39-13 vote ...
Cached Medicine News:Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2Health News:New NeoGraft™ Device Improves Hair Transplants 2Health News:New NeoGraft™ Device Improves Hair Transplants 3Health News:Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year 2Health News:New CME guidelines advise paradigm shift in physician education 2Health News:New CME guidelines advise paradigm shift in physician education 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 2Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 4Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 2Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 3
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Inquire...
Medicine Products: